Antibiotic resistance profile of Enterobacter in hospitals across China：data from CHINET Antimicrobial Resistance Surveillance Program from 2005 through 2014
10.16718/j.1009-7708.2016.03.007
- VernacularTitle:2005-2014年CHINET肠杆菌属细菌耐药性监测
- Author:
Lei TIAN
;
Zhongju CHEN
;
Ziyong SUN
;
Yingchun XU
;
Xiaojiang ZHANG
;
Yuxing NI
;
Jingyong SUN
;
Fu WANG
;
Demei ZHU
;
Yuanhong XU
;
Jilu SHEN
;
Hong ZHANG
;
Jing KONG
;
Qing YANG
;
Lianhua WEI
;
Ling WU
;
Zhidong HU
;
Jin LI
;
Chuanqing WANG
;
Aimin WANG
;
Chao ZHUO
;
Danhong SU
;
Yi XIE
;
Mei KANG
;
Bin SHAN
;
Yan DU
;
Zhaoxia ZHANG
;
Ping JI
;
Yunjian HU
;
Xiaoman AI
;
Yunzhuo CHU
;
Sufei TIAN
;
Bei JIA
;
Wenxiang HUANG
;
Yunsong YU
;
Jie LIN
;
Yanqiu HAN
;
Sufang GUO
- Publication Type:Journal Article
- Keywords:
bacterial resistance surveillance;
Enterobacter;
carbapenem-resistantEnterobacter
- From:
Chinese Journal of Infection and Chemotherapy
2016;16(3):275-283
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the distribution and antibiotic resistance proifle of clinicalEnterobacter isolates using the data from CHINET during the period from 2005 through 2014.Methods A total of 20 558 clinical strains ofEnterobacter spp. were collected from 2005 to 2014 in CHINET Antimicrobial Resistance Surveillance Program. Antimicrobial susceptibility testing was performed with Kirby-Bauer or minimum inhibitory concentration method. The results were analyzed according to CLSI 2014 breakpoints.ResultsEnterobacter cloacae andEnterobacter aerogenes accounted for 71.1% (14 617/20558) and 20.1% (4 129/20 558) of all theEnterobacterisolates, respectively. The proportion ofEnterobacter spp. increased with time from 3.5% in 2005 to 4.3% in 2014. The main source of the isolates was respiratory tract, accounting for 55.2% (11 358/20 558). More than 90% of theEnterobacterisolates were resistant to cefazolin and cefoxitin, but less than 30% of the strains were resistant to cefepime, piperacillin-tazobactam, cefoperazone-sulbactam, amikacin, gentamicin, ciprolfoxacin, meropenem, imipenem and ertapenem. TheEnterobacterisolates showed a trend of declining resistance to most antibiotics except ertapenem and meropenem. The resistance proifle ofEnterobacterisolates varied with departments where they were isolated. The strains from ICU and Department of Surgery were relatively more resistant to antibiotics. The prevalence of multi-drug resistant (MDR) strains was decreasing, but the prevalence of carbapenem-resistantEnterobacter (CRE, resistant to any of imipenem, meropenem or ertapenem) was increasing. The MDR and CRE strains were primarily isolated from ICU and Department of Surgery. At least 30% of the MDREnterobacter strains were resistant to any of the antimicrobial agents tested except meropenem, imipenem and ertapenem and at least 35% of the CRE strains were resistant to any of the antimicrobial agents tested except amikacin and ciprolfoxacin.Conclusions TheEnterobacter isolates in CHINET Antimicrobial Resistance Surveillance Program showed decreasing resistance to most of the antimicrobial agents tested since 2011, but the prevalence of CRE strains increased progressively. Effective measures should be carried out to prevent the spread of CRE strains in hospitals.
